Loading…

Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye

Aim: To determine the duration of residence of triamcinolone in the vitrectomised eye. Methods: 23 eyes of 23 patients underwent intravitreal injection of high dose (20 mg) decanted triamcinolone acetonide (Kenalog) at the conclusion of vitrectomy surgery or in previously vitrectomised eyes with mac...

Full description

Saved in:
Bibliographic Details
Published in:British journal of ophthalmology 2006-06, Vol.90 (6), p.705-708
Main Authors: Kosobucki, B R, Freeman, W R, Cheng, L
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: To determine the duration of residence of triamcinolone in the vitrectomised eye. Methods: 23 eyes of 23 patients underwent intravitreal injection of high dose (20 mg) decanted triamcinolone acetonide (Kenalog) at the conclusion of vitrectomy surgery or in previously vitrectomised eyes with macular oedema from diabetes, uveitis, cataract surgery, or other surgery. Results: The median time to disappearance of triamcinolone in the vitrectomised eye was 113 days (95% confidence interval (CI) 85 to 191). In the phakic eyes the median time to disappearance was 191 days (95% CI 148 to 191). In the pseudophakic eyes the median time to disappearance was 102 days (95% CI 85 to 113). This difference was not significant (p = 0.12). There were no cases of endophthalmitis or severe inflammatory reaction. Five eyes (22%) experienced intraocular pressure rise ⩾10 mm Hg. Conclusions: High dose decanted intravitreal triamcinolone has a median residence time of 113 days in the vitrectomised eye. Although this appears to be shorter than in the non-vitrectomised eye, this study suggests that a sufficient duration of action will be present to be clinically useful.
ISSN:0007-1161
1468-2079
DOI:10.1136/bjo.2005.088278